Amneal Pharmaceuticals (AMRX) Long-Term Deferred Tax (2017 - 2019)

Amneal Pharmaceuticals' Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $391.9 million for Q2 2019.

• On a quarterly basis, Long-Term Deferred Tax rose 4.86% year-over-year to $391.9 million in Q2 2019; TTM through Jun 2019 was $391.9 million, a 4.86% increase from a year earlier, with the FY2018 full-year figure at $373.2 million, up 41454.45% from the prior year.
• Long-Term Deferred Tax rose to $391.9 million in Q2 2019 per AMRX's latest filing, from $382.9 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $391.9 million in Q2 2019 and bottomed at $898000.0 in Q4 2017.
• The 3-year median for Long-Term Deferred Tax is $373.4 million (2018), against an average of $314.8 million.
• Across the five-year window, Long-Term Deferred Tax surged 41454.45% in 2018 and grew 4.86% in 2019, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $898000.0 in 2017, then jumped by 41454.45% to $373.2 million in 2018, then gained by 5.02% to $391.9 million in 2019.
• Per Business Quant, the three latest AMRX Long-Term Deferred Tax figures stand at $391.9 million (Q2 2019), $382.9 million (Q1 2019), and $373.2 million (Q4 2018).